Darbepoetin Alfa (Aranesp) (Pharmacology Notes) (Drug Overview)

Darbepoetin Alfa (Aranesp) (Pharmacology Notes) (Drug Overview)

The Food and Drug Administration (FDA) approved darbepoetin alfa (Aranesp) for treatment of anemia as sociated with chronic renal failure (CRF) in patients on dialysis and patients not on dialysis (1). The manufacturer of the drug also filed an application with the FDA on September 18, 2001, to receive an indication for treatment of anemia […]

Drotrecogin Alfa (Activated): The First Fda-Approved Treatment for Severe Sepsis (Pharmacology Notes) (Drug Overview)

Drotrecogin Alfa (Activated): The First Fda-Approved Treatment for Severe Sepsis (Pharmacology Notes) (Drug Overview)

Drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, Ind) is a recombinant form of human activated protein C. It was approved by the Food and Drug Administration in the last quarter of 2001 for the reduction of mortality due to severe sepsis in adult patients who are at high risk of death (1). This […]